← Leaderboards
Ian J Sarembock
Adenosine Therapeutics, Llc
$1,411,850
Attributed
$1,411,850
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,411,850 · 2
By mechanism
R01$1,311,850 · 1
R41$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Adenosine Therapeutics, Llc
Same institution · by research overlap
- Robert D Thompson$4,905,559
- George Allan Beller$2,554,046
- William M Scheld$633,055
- Ray A Olsson$423,348
- Shannon P Williams$1,276,772
Others in their field
Top investigators on “Immunocytochemistry”
- Anthony N Van Den Pol · Yale University$15,503,444
- Fred H Gage · Brown University$13,660,280
- Hongjun Song · Johns Hopkins University$12,462,321
- Muhammad Ashraf · University Of Cincinnati$12,412,642
- Eliezer Masliah · University Of California San Diego$12,284,679
- Eric Klann · University Of Pittsburgh At Pittsburgh$9,943,789
Research focus
ImmunocytochemistryLaboratory MouseArteryArtery StenosisBlood Vessel DisorderBone Marrow TransplantationCardiovascular SurgeryCell Growth RegulationCell MigrationVascular EndotheliumApolipoprotein EGene Deletion MutationGene ExpressionGene TargetingGenetically Modified AnimalsIatrogenic DiseaseMacrophageMagnetic Resonance ImagingMonoclonal AntibodyNeutrophilSelectinsDisease /Disorder ModelFlow CytometryCardiovascular Injury
Grant awards (5)
SELECTINS ROLE IN VASCULAR INJURY IN GENE-TARGETED$338,161
R01 · FY2004 · HL
SELECTINS ROLE IN VASCULAR INJURY IN GENE-TARGETED$328,039
R01 · FY2003 · HL
SELECTINS ROLE IN VASCULAR INJURY IN GENE-TARGETED MICE$318,213
R01 · FY2002 · HL
SELECTINS ROLE IN VASCULAR INJURY IN GENE-TARGETED MICE$327,437
R01 · FY2001 · HL
NOVEL ADENOSINE A2A AGONISTS IN VASCULAR PROTECTION$100,000
R41 · FY2000 · HL